Daniel Friedman, MD
Epilepsy · New York, NYNPI 1407900152
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $61,979 of the $66,439 with a category attached, or 93.3%. 11 manufacturers reported payments, led by Eisai Inc. at 33.5% of the total. Reporting peaked in 2019 at $23,872 and has fallen 82.3% since, to $4,217 in 2025. Among epilepsy clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $1444.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$22K
- Neurocrine Biosciences, Inc.$9K
- UCB, Inc.$8K
- Jazz Pharmaceuticals Inc.$7K
- Neurelis, Inc.$7K
- Biogen$7K
- plus $6K from 5 others
Across 2 payments — averaging $2075.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neuropace, Inc.$4K
- Biogen$250
What the payments were for
- Consulting fees$61,97993%
- Speaking & faculty fees$3,0005%
- Travel & lodging$9941%
- Food & beverage$4661%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 4 | $22,275 |
| Neurocrine Biosciences, Inc. | 10 | $9,300 |
| UCB, Inc. | 8 | $7,664 |
| Jazz Pharmaceuticals Inc. | 6 | $7,320 |
| Neurelis, Inc. | 5 | $7,070 |
| Biogen | 3 | $6,547 |
| SK Life Science, Inc. | 1 | $3,000 |
| UCB SA | 4 | $1,375 |
| Neuropace, Inc. | 3 | $1,021 |
| Aquestive Therapeutics, Inc. | 1 | $840 |
| Philips North America LLC | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VALTOCO$6,939
- Epidiolex$6,500
- RNS Neurostimulator Kit$1,021
How this compares
$66,439 in reported general payments places this provider in the 90th percentile of 21 epilepsy providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 124 | $244,518 |
| Lamictal XrLamotrigine | 96 | $207,359 |
| EpidiolexCannabidiol (Cbd) | 36 | $127,627 |
| BriviactBrivaracetam | 45 | $116,054 |
| FinteplaFenfluramine Hcl | 12 | $107,354 |
| Trokendi XrTopiramate | 26 | $65,158 |
| VimpatLacosamide | 31 | $64,065 |
| AptiomEslicarbazepine Acetate | 13 | $54,535 |
| FelbatolFelbamate | 15 | $43,835 |
| FycompaPerampanel | 27 | $37,556 |
| ValtocoDiazepam | 23 | $33,754 |
| Lacosamide | 222 | $32,517 |
| NayzilamMidazolam | 26 | $29,806 |
| Depakote ErDivalproex Sodium | 15 | $26,138 |
| Lamictal OdtLamotrigine | 16 | $22,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| UCB, Inc.Briviact, Fintepla, Vimpat, Nayzilam | $7,664 | $317,280114 claims |
| SK Life Science, Inc.Xcopri | $3,000 | $244,518124 claims |
| Eisai Inc.Fycompa | $22,275 | $37,55627 claims |
| Neurelis, Inc.Valtoco | $7,070 | $33,75423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 epilepsy providers in New York.
Other epilepsy in New York
- Patricia DuganNew York$97K
- Christopher ElderNew York$41K
- Hai ChenNew York$1K
- Priya PurushothamanNew York$1K
- Robert McInnisNew York$801
- Kyung KimNew York$556
- Robert GloverBuffalo$88K
- Sheryl HautBronx$61K
- Benjamin BlondStony Brook$40K
- Andres Rodriguez-RuizBrooklyn$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.